| 00:00:00 | Nanotechnology and oncology |
| 00:01:52 | Nanotechnology and oncology |
| 00:02:41 | Abstract |
| 00:03:07 | One hope – Press release: http://tinyurl.com/a3dzh4a |
| 00:04:43 | Careful with the hype – nanobotsRemember the basics….. |
| 00:05:25 | What is cancer? See: http://www.cancer.gov/ |
| 00:06:08 | Statistics |
| 00:07:14 | Balanced scorecardhttp://progressreport.cancer.gov/trends-glance.asp |
| 00:08:13 | Types |
| 00:09:00 | The Good News |
| 00:10:11 | Nanotechnology |
| 00:11:22 | Cancer Nanotechnology |
| 00:12:45 | Solubility |
| 00:13:32 | Solubility |
| 00:14:41 | Figure 2 - Factors that lead to increased solubility and permeability of Class II and IV, and Class III drugs |
| 00:15:38 | “The magic bullet” |
| 00:16:22 | Diversion: The original magic bullet |
| 00:17:35 | Dendrimers |
| 00:18:51 | Active TargetingMTX = methotrexate. It can be conjugated to a G5 PAMAM dendrimer |
| 00:19:53 | Drug or Device? |
| 00:20:04 | Size Matters |
| 00:21:05 | Mauro Ferrari “CANCER NANOTECHNOLOGY: OPPORTUNITIES AND CHALLENGES” NATURE REVIEWS | CANCER VOLUME 5 | MARCH 2005 | 161 |
| 00:21:49 | The potential |
| 00:22:36 | Nanotechnology and BiologyWhy? |
| 00:23:41 | Untitled |
| 00:24:00 | One potential application |
| 00:25:04 | Jennifer H. Grossman. Scott E. McNeil “Nanotechnology in Cancer Medicine”Phys. Today 65(8), 38 (2012); doi: 10.1063/PT.3.1678 |
| 00:25:51 | M M Yallapu, M Jaggi, S C Chauhan “Scope of nanotechnology in ovarian cancer therapeutics” Journal of Ovarian Research , 3:19 (2010) |
| 00:26:41 | Nanomedicine Pipeline |
| 00:27:06 | S A Mousa, D J Bharali “Nanotechnology-Based Detection and Targeted Therapy in Cancer: Nano-Bio Paradigms and Applications” Cancers 2011, 3, 2888-2903; doi:10.3390/cancers3032888 |
| 00:27:32 | S A Mousa, D J Bharali “Nanotechnology-Based Detection and Targeted Therapy in Cancer: Nano-Bio Paradigms and Applications” Cancers 2011, 3, 2888-2903; doi:10.3390/cancers3032888 |
| 00:28:33 | The big picture$ |
| 00:29:13 | PCA’sNote 4 |
| 00:30:18 | What did ANSI-NSP say in 2004? (The unreadable slide!) |
| 00:30:34 | ANSI-NSP (Summary/Readable) |
| 00:31:28 | NNI - http://www.nano.gov/node/748 |
| 00:31:58 | What is the NNI? |
| 00:33:04 | NNI - Program Areas |
| 00:33:50 | The US perspectiveNational Cancer Institute |
| 00:34:38 | The big picture |
| 00:35:03 | The big picture |
| 00:35:41 | Centers of Cancer Nanotechnology Excellence |
| 00:36:12 | NCI Alliance |
| 00:36:31 | NCI |
| 00:37:20 | NCI - successes |
| 00:38:23 | TONIC et al |
| 00:39:01 | Training programs |
| 00:39:28 | Untitled |
| 00:40:23 | NCI Alliance for Nanotechnology in Cancer Goals: 2010-2015 |
| 00:41:16 | NCL Objectives |
| 00:41:43 | NCL Concept of Operations |
| 00:41:48 | In Vitro Cascade |
| 00:42:36 | NCL Assay Cascade |
| 00:43:03 | Nanotech Points of Discussion |
| 00:43:57 | Untitled |
| 00:44:34 | Voluntary Consensus Standards |
| 00:44:53 | The role of ASTM |
| 00:45:24 | Standards |
| 00:46:54 | See the DLS video |
| 00:47:21 | Summary |
| 00:48:33 | Selected reference list |
| 00:49:09 | Contact Information |
One of the great hopes for nanotechnology is in the treatment of cancer. We will look at some of the programs and technologies being explored and the importance of nanotechnology in this area.